Kinnate Biopharma Intrinsic Stock Value – Kinnate Biopharma Rated Upgraded Despite Challenging Times
December 17, 2023
🌧️Trending News
Kinnate Biopharma ($NASDAQ:KNTE) has been making steady progress, but not yet ready for an upgrade in its rating. Despite the challenging economic and market conditions, the company has managed to maintain its financial stability and focus on its core business activities. As a result, an upgrade in its rating has been recommended by analysts. Kinnate Biopharma is a biotechnology company based in California, USA. It specializes in developing and commercializing innovative treatments for serious illnesses. The company’s focus areas include gene therapy, cellular immunotherapy, gene editing and bioinformatics. Its products are designed to address the most pressing medical problems, such as cancer, rare diseases, and neurological disorders. It also offers a suite of research tools and services to help accelerate drug development.
Kinnate Biopharma’s strong financial performance and innovative product portfolio have enabled it to make steady progress even during these difficult times. Despite the pandemic, the company has continued to make strides in its research and development efforts, and has secured several major collaborations with leading pharmaceutical companies for joint drug development projects. The company’s financial stability and focus on core activities gives it a solid foundation to further grow its business. Moreover, its ambitious initiatives in drug discovery and development have enabled it to stay ahead of the competition. Overall, Kinnate Biopharma’s rating upgrade reflects its steady progress despite challenging times. With its strong financials and innovative product portfolio, the company is well-positioned to continue delivering value to its shareholders in the long-term.
Market Price
Despite challenging times, Kinnate Biopharma‘s stock has been rated upgraded by analysts. On Tuesday, KINNATE BIOPHARMA opened at $2.2 and closed at $2.2, down by 3.1% from its last closing price of 2.3. This is a slight decrease from the overall market, however the upgrade is a sign of confidence in the company’s potential in the coming future.
Investors have taken notice of this upgrade and the stock is currently making a slight recovery from the drop. It remains to be seen if the stock will continue to increase in value after this upgrade. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kinnate Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -127.15 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kinnate Biopharma. More…
| Operations | Investing | Financing |
| -106.43 | 104.74 | -7.62 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kinnate Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 190.71 | 18.29 | 3.66 |
Key Ratios Snapshot
Some of the financial key ratios for Kinnate Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -44.8% | -43.5% |
Analysis – Kinnate Biopharma Intrinsic Stock Value
At GoodWhale, we have taken a deep dive into KINNATE BIOPHARMA‘s fundamentals to provide a comprehensive analysis of the company’s financial performance and outlook. Our proprietary Valuation Line indicates that KINNATE BIOPHARMA’s fair value share price is around $7.1. More…
Peers
The company’s lead product candidate, IPI-549, is an orally-available, small molecule inhibitor of PI3Kγ. The company is also developing IPI-145, an inhibitor of Bruton’s tyrosine kinase (BTK), and IPI-180, an inhibitor of Janus kinases (JAKs). The company’s competitors include Pliant Therapeutics Inc, Epizyme Inc, Gossamer Bio Inc.
– Pliant Therapeutics Inc ($NASDAQ:PLRX)
Pliant Therapeutics, Inc. focuses on the development of therapies for the treatment of fibrotic diseases. The company’s lead product candidate is PLI-300, an orally-administered small molecule that inhibits the production of collagen by blocking the interaction between the alpha2beta1 integrin and collagen. PLI-300 is in Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and scleroderma. The company was founded in 2015 and is headquartered in San Francisco, California.
– Epizyme Inc ($NASDAQ:GOSS)
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is $990.28 million and its ROE is -1952.91%. Gossamer Bio’s lead product candidate, GB226, is a Phase 2b-ready monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.
Summary
Kinnate Biopharma is a biopharmaceutical company with a focus on developing treatments for cancer and other diseases. Despite recently righting some of its financial struggles, analysts still suggest it may not be the right time to invest in the company. For investors considering Kinnate Biopharma, the stock is currently seen as a risky bet. The company has promising products in development pipeline and may provide attractive returns over time, however investors should do thorough research and weigh their options before making an investment decision.
